

Summary of 2nd Quarter Financial Results for year ended March 31, 2011 (Japan GAAP) (Unaudited)

October 29, 2010

Company name: Mitsubishi Tanabe Pharma Corporation
 Stock exchange listings (Section): Tokyo, Osaka (First Sections)
 Securities code number: 4508
 URL: <http://www.mt-pharma.co.jp/>
 Representative: Name: Michihiro Tsuchiya
 Title: President and Representative Director
 For further information, please contact: Name: Yoshihisa Sasou
 Title: General Manager, Corporate Communications Department
 Telephone: (06) 6205-5211

Planned date of filing of quarterly securities report: November 5, 2010
 Planned date of start of dividend payments: December 1, 2010
 Provision of supplementary explanatory materials for quarterly results: Yes
 Quarterly results presentation: Yes (for institutional investors and investment analysts)

Note: Amounts less than ¥ 1 million have been rounded.

1. Results for 2nd Quarter (April 1, 2010 to September 30, 2010)

(1) Consolidated Business Results

	Net sales		Operating income		Ordinary income	
	Yen million	% change	Yen million	% change	Yen million	% change
2nd Quarter of Fiscal 2010	204,684	3.3	40,155	46.3	40,473	45.0
2nd Quarter of Fiscal 2009	198,239	(3.9)	27,456	(19.4)	27,910	(20.6)

	Net income		Net income per share	Net income per share (diluted)
	Yen million	% change	Yen	Yen
2nd Quarter of Fiscal 2010	22,704	67.5	40.46	-
2nd Quarter of Fiscal 2009	13,552	(17.3)	24.15	-

(Note) Percentage changes in the above list show change in comparison with the previous 2nd quarter.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Yen million	Yen million	%	Yen
30-Sep-10	810,923	687,942	84.1	1,215.47
31-Mar-10	796,858	676,813	84.1	1,194.79

(Note) Shareholders' equity ¥681,992 million (¥670,470 million in fiscal 2009)

2. Dividends

(Record date)	Dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year-end	For the year
	Yen	Yen	Yen	Yen	Yen
Fiscal 2009	-	14.00	-	14.00	28.00
Fiscal 2010	-	14.00	-	-	-
Fiscal 2010 (projected)	-	-	-	14.00	28.00

(Note) Revision to dividend forecast in the quarter under review: No

3. Forecasts for Fiscal 2010 (April 1, 2010 to March 31, 2011)

	Net sales		Operating income		Ordinary income	
	Yen million	% change	Yen million	% change	Yen million	% change
Full year	401,000	(0.9)	67,000	9.0	67,000	8.7

	Net income		Net income per share
	Yen million	% change	Yen
Full year	35,500	17.3	63.26

(Note) Revision to consolidated results forecast in the quarter under review: No

4. Other

(For details, please see "Others" on page 5 of the summary of 2nd quarter financial results (supplement))

(1) Significant change involving subsidiaries during the period: No

Note: Indicates whether or not there was any change in designated subsidiaries accompanying changes in the scope of consolidation in the quarter under review.

(2) Application of simplified accounting methods or of special accounting methods in the preparation of quarterly financial statements: Yes

Note: Indicates whether or not the Company applied simplified accounting methods or special accounting methods in the preparation of quarterly financial statements.

(3) Changes in accounting principles, procedures, method of presentation

1. Change accompanying revision of accounting standards: Yes

2. Other changes: No

Note: Indicates whether or not there were any changes in accounting principles, procedures, or method of presentation associated with the preparation of the quarterly consolidated financial statements.

(Items noted in the Changes in the Basis of Presenting Quarterly Consolidated Financial Statements section)

(4) Number of shares issued (common stock)

1. Number of shares issued at the end of the period (including treasury stock)

2nd Quarter of fiscal 2010	561,417,916 shares	Fiscal 2009	561,417,916 shares
----------------------------	--------------------	-------------	--------------------

2. Number of shares of treasury stock at the end of the period

2nd Quarter of fiscal 2010	324,358 shares	Fiscal 2009	256,440 shares
----------------------------	----------------	-------------	----------------

3. Average number of shares of during the period (six months)

2nd Quarter of fiscal 2010	561,147,957 shares	2nd Quarter of fiscal 2009	561,163,283 shares
----------------------------	--------------------	----------------------------	--------------------

*Note regarding implementation of quarterly review procedures

At the time when this summary of 2nd quarter financial results was released, the review procedures were in progress for the quarterly financial statements in accordance with the Financial Instruments and Exchange Act.

*Explanation regarding the appropriate use of results forecasts and other matters of special note

In these materials, forecasts of results and other statements about the future are forward-looking statements based on a number of assumptions and beliefs in light of the information available to management as of the date of release of the materials and are subject to risks and uncertainties. Actual financial results may differ materially from these forecasts depending on a number of important factors, including economic conditions in the Company's fields of business. For matters related to results forecasts, please see page 4.

Contents of supplement

- 1. Qualitative Information, Financial Statements, etc.1
 - (1) Qualitative information about consolidated results of operations1
 - (2) Qualitative information about consolidated financial position3
 - (3) Qualitative information about consolidated results forecasts.....4
- 2. Other5
 - (1) Significant changes involving subsidiaries during the period
(changes in designated subsidiaries accompanying changes in the scope of consolidation).....5
 - (2) Application of simplified accounting methods or of special accounting methods
in the preparation of quarterly financial statements5
 - (3) Changes in accounting principles, procedures, method of presentation associated
with the preparation of the quarterly consolidated financial statements5
- 3. Consolidated Financial Statements6
 - (1) Consolidated balance sheets.....6
 - (2) Consolidated statements of income (first six months).....8
 - (3) Consolidated statements of cash flows9
 - (4) Note regarding going concern assumption..... 10
 - (5) Segment Information 10
 - (6) Note regarding substantial change in shareholders' equity..... 11

1. [Qualitative Information, Financial Statements, etc.]

(1) Qualitative information about consolidated results of operations

In the pharmaceutical industry, NHI drug prices were revised in April 2010, and a system offering a pricing premium for newly developed drugs was introduced on a trial basis. Consequently, NHI drug prices were reduced by an industrywide average of 5.75%, and additional price cuts were implemented for long-term listed drugs. Moreover, with such factors as intensified competition among companies and further measures to promote the use of generic drugs, market conditions remain challenging.

In June, the Company and its consolidated subsidiary Bipha Corporation submitted business improvements plans to the Minister of Health, Labour and Welfare as to the administrative action, received in April, in regard to a violation of the Pharmaceutical Affairs Act. Under the business improvement plans, the entire Group will work to implement thorough recurrence prevention measures and to do its utmost to regain the trust of society.

Consolidated results in the first six months of the fiscal year ended March 31, 2011 (April 1, 2010 to September 30, 2010) were as follows.

(millions of yen)

	First six months of previous fiscal year	First six months of current fiscal year	Increase/ decrease	% change
Net Sales	198,239	204,684	6,445	3.3
Cost of sales	71,005	77,835	6,830	9.6
Cost of sales ratio	35.8%	38.0%		
Gross profit	127,234	126,849	(385)	(0.3)
SG&A expenses	99,778	86,694	(13,084)	(13.1)
Operating Income	27,456	40,155	12,699	46.3
Non-operating income/loss	454	318	(136)	
Ordinary Income	27,910	40,473	12,563	45.0
Extraordinary income/loss	(4,591)	(3,295)	1,296	
Net Income	13,552	22,704	9,152	67.5

【Net sales】

Net sales increased 3.3%, or ¥6.4 billion, year-on-year, to ¥204.6 billion.

(millions of yen)

	First six months of previous fiscal year	First six months of current fiscal year	Increase/ decrease	% change
Pharmaceuticals	193,435	199,836	6,401	3.3
Domestic ethical drugs	172,100	179,144	7,044	4.1
Overseas ethical drugs	11,332	11,293	(39)	(0.3)
OTC products	2,660	2,871	211	7.9
Others	7,343	6,528	(815)	(11.1)
Others	4,804	4,848	44	0.9

- In the pharmaceuticals segment, net sales were ¥199.8 billion, up 3.3%, or ¥6.4 billion, year-on-year.
- The domestic sales of ethical drugs were up 4.1%, or 7.0 billion, year-on-year. Although NHI drug prices were revised in April 2010, favorable sales were recorded by such products as Remicade, an anti-TNF α monoclonal antibody; Radicut, a cerebral neuroprotectant; Maintate, a selective β 1 antagonist; and Talion, a treatment for allergic disorders. In addition, higher sales were recorded by generic drugs as well as by JEBIK V, a freeze-dried, cell-culture derived Japanese encephalitis vaccine, which the government reinstated as a recommended vaccination in April 2010.
- Sales of others in pharmaceuticals were down 11.1%, or ¥0.8 billion, year-on-year, due to the recording in the previous fiscal year of one-time revenue from a licensing agreement.

【Operating income】

Operating income increased 46.3%, or ¥12.6 billion, year-on-year, to ¥40.1 billion.

- Net sales rose ¥6.4 billion. On the other hand, gross profit declined slightly, to ¥126.8 billion due to the influence of NHI drug price revisions and other factors. The cost of sales ratio worsened by 2.2 percentage points, to 38.0%.
- Accompanying a change in a licensing contract, the Company made a one-time payment of about ¥10.0 billion in the previous fiscal year. In the period under review, R&D expenses decreased substantially year-on-year, and labor costs were down due to such factors as lower retirement benefits expense. In addition, sales promotion and other expenses also decreased. As a result, SG&A expenses were down 13.1%, or ¥13.0 billion, to ¥86.6 billion. R&D expenses were ¥32.4 billion, accounting for 15.9% of net sales.

【Ordinary income and net income】

Ordinary income was up 45.0%, or ¥12.5 billion, year-on-year, to ¥40.4 billion, and net income was up 67.5%, or ¥9.1 billion, year-on-year, to ¥22.7 billion.

- Extraordinary losses were ¥3.7 billion, including loss on valuation of investment in securities of ¥2.4 billion and loss related to business suspension for Medway injection recombinant human serum albumin preparation of ¥0.7 billion. In the previous fiscal year, the Company recorded extraordinary losses of ¥4.6 billion, such as impairment loss accompanying head office relocation, restructuring expenses, and loss related to business suspension in regard to Medway injection. Consequently, in the period under review, the net balance of extraordinary items improved by ¥1.2 billion year-on-year.

(2) Qualitative information about consolidated financial position

【Balance sheets】

(millions of yen)

	End of 2 nd quarter (End of September 2010)	End of previous fiscal year (End of March 2010)	Increase/ decrease
Current assets	365,636	344,249	21,387
Fixed assets	445,287	452,609	(7,322)
Total assets	810,923	796,858	14,065
Liabilities	122,981	120,045	2,936
Net assets	687,942	676,813	11,129
Total liabilities and net assets	810,923	796,858	14,065

Total assets at the end of the second quarter were ¥810.9 billion, an increase of ¥14.0 billion from the end of the previous fiscal year. Major factors causing changes in the balance sheet in comparison with the previous year-end were as follows.

- Marketable securities and inventories increased. Consequently, total current assets were up ¥21.3 billion, to ¥365.6 billion.
- Fixed assets were down ¥7.3 billion from the previous fiscal year-end, to ¥445.2 billion, as property, plant and equipment and intangible fixed assets including goodwill decreased by the depreciation and the amortization.
- Notes and accounts payable-trade, and income taxes payable increased. On the other hand, accounts payable-other and reserve for HCV litigation declined. Consequently, total liabilities were up by ¥2.9 billion, to ¥122.9 billion.
- Total net assets were up by ¥11.1 billion, to ¥687.9 billion. Net income was ¥22.7 billion, and dividends paid totaled ¥7.8 billion. As a result, retained earnings increased ¥14.8 billion. In addition, total valuation and translation adjustments declined by ¥3.2 billion. The equity ratio was 84.1%, compared with 84.1% a year earlier.

【Cash flows】

(millions of yen)

		First six months of previous fiscal year	First six months of current fiscal year	Increase/ decrease
	Operating activities	2,846	32,900	30,054
	Investing activities	(37,736)	(24,878)	12,858
	Financing activities	(9,002)	(7,784)	1,218
	Change in cash and cash equivalents	(43,373)	(465)	42,908
	At beginning of year	116,903	62,958	(53,945)
	At end of period	73,720	62,557	(11,163)

Net decrease in cash and cash equivalents was ¥0.4 billion, and the balance of cash and cash equivalents at the end of the period under review was ¥62.5 billion.

- Net cash provided by operating activities was ¥32.9 billion. Cash inflows included income before income taxes and minority interests of ¥37.1 billion, depreciation and amortization of ¥6.0 billion, and amortization of goodwill of ¥5.0 billion, and increase in notes and accounts payable-trade of ¥9.2 billion, while cash outflows included income taxes paid of ¥10.3 billion, increase in inventories of ¥4.1 billion, decrease in reserve for HCV litigation of ¥3.2 billion, and decrease in accounts payable-other of ¥6.1 billion.
- Net cash used in investing activities was ¥24.8 billion, due in part to purchase of marketable securities and purchase of investment in securities for investment purposes.
- Net cash used in financing activities was ¥7.7 billion, due in part to dividends paid of ¥7.8 billion.

(3) Qualitative information about consolidated results forecasts

There are no revisions to the consolidated results forecasts that were announced on October 4, 2010.

Consolidated results forecasts for current fiscal year (released on October 4, 2010)

(millions of yen)

	Results in previous fiscal year	Forecast for current fiscal year	Increase/ decrease	% change
Net Sales	404,747	401,000	(3,747)	(0.9)
Operating Income	61,475	67,000	5,525	9.0
Ordinary Income	61,649	67,000	5,351	8.7
Net Income	30,253	35,500	5,247	17.3

2. Other

- (1) Significant changes involving subsidiaries during the period (changes in designated subsidiaries accompanying changes in the scope of consolidation):

Not applicable.

- (2) Application of simplified accounting methods or of special accounting methods in the preparation of quarterly financial statements:

- Method of calculation of income taxes, deferred tax assets, and deferred tax liabilities

The calculation of income tax payments, deferred tax assets, and deferred tax liabilities is based on the sum of important adjustment and tax credit items.

In regard to judgments about the recoverability of deferred tax assets, in the event that there are no marked changes in the management environment, etc., since the end of the previous fiscal year and there are no marked changes in the occurrence of temporary differences, the judgments utilize a method based on the future results forecasts used in the previous consolidated settlement of accounts and on tax planning. In the event that there are marked changes in the management environment, etc., since the end of the previous fiscal year or there are marked changes in the occurrence of temporary differences, the judgements utilize the a method based on the future results forecasts used in the previous consolidated settlement of accounts and on tax planning as well as the influence of the marked changes.

- (3) Changes in accounting principles, procedures, method of presentation associated with the preparation of the quarterly consolidated financial statements:

- Application of Accounting Standards for Asset Retirement Obligations

From the first quarter, the Company applies "Accounting Standards for Asset Retirement Obligations" (ASBJ Statement No. 18, March 31, 2008) and "Guidance on Accounting Standards for Asset Retirement Obligations" (ASBJ Guidance No. 21, March 31, 2008). This change will not have a significant effect on results.

3. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(millions of yen)

Year Accounts	As of September 30, 2010	As of March 31, 2010
	Amount	Amount
Assets		
Current assets		
Cash and time deposits	24,922	22,792
Notes and accounts receivable-trade	126,861	126,227
Marketable securities	80,568	59,726
Merchandise and finished goods	55,574	52,774
Work in process	1,130	1,298
Raw materials and supplies	20,453	19,094
Deposits	39,077	46,271
Deferred income taxes	12,108	11,394
Other	4,980	4,714
Allowance for doubtful receivables	(37)	(41)
Total current assets	365,636	344,249
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	39,682	41,359
Machinery, equipment and vehicles, net	16,758	18,932
Tools, furniture and fixtures, net	3,951	4,489
Land	51,089	50,931
Lease assets, net	27	31
Construction in progress	3,632	1,476
Total property, plant and equipment	115,139	117,218
Intangible fixed assets		
Goodwill	120,758	125,765
Other	3,683	3,849
Total intangible fixed assets	124,441	129,614
Investments and other assets		
Investment in securities	139,474	139,133
Deferred income taxes	13,578	14,300
Prepaid pension expenses	38,625	36,730
Other	14,070	15,658
Allowance for doubtful receivables	(40)	(44)
Total investments and other assets	205,707	205,777
Total fixed assets	445,287	452,609
Total assets	810,923	796,858

(millions of yen)

Year Accounts	As of	As of
	September 30, 2010	March 31, 2010
	Amount	Amount
Liabilities		
Current liabilities		
Notes and accounts payable-trade	36,400	27,557
Short-term loans	2,610	2,410
Current maturities of long-term loans	15	30
Accounts payable-other	13,592	20,202
Income taxes payable	12,958	11,080
Reserve for employees' bonuses	11,454	11,155
Other reserves	142	172
Other	6,580	5,161
Total current liabilities	83,751	77,767
Long-term liabilities		
Deferred income taxes	11,478	11,267
Accrued retirement benefits for employees	12,499	13,159
Accrued retirement benefits for directors and corporate auditors	5	4
Reserve for health management allowances for HIV compensation	1,627	1,627
Reserve for health management allowances for SMON compensation	3,914	4,205
Reserve for HCV litigation	7,480	10,689
Other	2,227	1,327
Total long-term liabilities	39,230	42,278
Total liabilities	122,981	120,045
Net assets		
Shareholders' equity		
Common stock	50,000	50,000
Capital surplus	451,186	451,185
Retained earnings	194,257	179,409
Treasury stock, at cost	(367)	(277)
Total shareholders' equity	695,076	680,317
Valuation and translation adjustments		
Unrealized holding gains on securities	(4,367)	(3,218)
Deferred (losses) gains on hedges	(1,503)	(378)
Translation adjustments	(7,214)	(6,251)
Total valuation and translation adjustments	(13,084)	(9,847)
Minority interests	5,950	6,343
Total net assets	687,942	676,813
Total liabilities and net assets	810,923	796,858

(2) Consolidated Statements of Income

(millions of yen)

Year Accounts	April 1, 2009 - September 30, 2009	April 1, 2010 - September 30, 2010
	Amount	Amount
Net sales	198,239	204,684
Cost of sales	71,005	77,835
Gross profit	127,234	126,849
Selling, general and administrative expenses		
Advertising expenses	1,450	1,363
Sales promotion expenses	5,629	5,312
Salaries and allowances	13,777	13,693
Provision for bonuses	6,017	6,013
Retirement benefit expenses	2,496	1,834
Provision for directors' retirement benefits	-	1
Depreciation and amortization	839	871
Research and development expenses	44,567	32,492
Amortization of goodwill	5,067	5,072
Other	19,936	20,043
Total selling, general and administrative expenses	99,778	86,694
Operating income	27,456	40,155
Non-operating income		
Interest income	932	801
Dividend income	434	473
Equity in earnings of affiliates	83	-
Other	358	468
Total non-operating income	1,807	1,742
Non-operating expenses		
Interest expense	16	7
Equity in losses of affiliates	-	34
Foreign exchange loss	233	263
Taxes and dues	-	213
Loss on disposal of property, plant and equipment	233	175
Donations	161	158
Other	710	574
Total non-operating expenses	1,353	1,424
Ordinary income	27,910	40,473
Extraordinary income		
Gain on sales of property, plant and equipment	-	277
Reversal of past year patent royalties	-	179
Gain on sales of investment in securities	77	-
Total extraordinary income	77	456
Extraordinary loss		
Loss on valuation of investment in securities	263	2,426
Loss related to business suspension	1,699	737
Special retirement expenses	-	448
Restructuring expenses	528	140
Impairment loss	1,824	-
Other	354	-
Total extraordinary losses	4,668	3,751
Income before income taxes and minority interests	23,319	37,178
Income taxes-current	9,923	12,892
Income taxes-deferred	589	1,759
Total income taxes	10,512	14,651
Income before minority interests	12,807	22,527
Minority interests	(745)	(177)
Net income	13,552	22,704

(3) Consolidated Statements of Cash Flows

(millions of yen)

Year Accounts	April 1, 2009 - September 30, 2009	April 1, 2010 - September 30, 2010
Cash flows from operating activities:		
Income before income taxes and minority interests	23,319	37,178
Depreciation and amortization	6,329	6,017
Impairment loss	1,824	-
Amortization of goodwill	5,067	5,072
Increase (decrease) in accrued retirement benefits for employees	(545)	(651)
Decrease (increase) in prepaid pension expenses	(266)	(1,895)
Increase (decrease) in allowance for doubtful receivables	(3)	(2)
Increase (decrease) in reserve for HCV litigation	(10,840)	(3,209)
Interest and dividend income	(1,366)	(1,274)
Interest expense	16	7
Loss (gain) on sales and disposal of fixed assets	172	(182)
Loss (gain) on sales of investment in securities	(77)	-
Loss (gain) on devaluation of investment in securities	263	2,426
Equity in (earnings) losses of affiliates	(83)	34
Decrease (increase) in notes and accounts receivable, trade	(4,349)	(942)
Decrease (increase) in inventories	(490)	(4,148)
Increase (decrease) in notes and accounts payable, trade	1,901	9,215
Increase (decrease) in accounts payable, other	(3,177)	(6,171)
Other, net	(1,564)	363
Subtotal	16,131	41,838
Interest and dividends received	1,385	1,390
Interest paid	(17)	(6)
Subsidy received	400	-
Income taxes paid	(15,053)	(10,322)
Net cash provided by (used in) operating activities	2,846	32,900
Cash flows from investing activities:		
Purchase of marketable securities	(29,480)	(38,918)
Proceeds from sales and redemption of marketable securities	15,134	43,009
Increase in time deposits	(978)	(8,510)
Decrease in time deposits	919	9,121
Increase in long-term deposits	(636)	(548)
Decrease in long-term deposits	-	569
Purchase of property, plant and equipment	(3,827)	(4,402)
Proceeds from sales of property, plant and equipment	12	467
Purchase of intangible fixed assets	(1,170)	(365)
Purchase of investment in securities	(20,300)	(28,504)
Proceeds from sales and redemption of investment in securities	1,521	3,162
Proceeds from sales of subsidiaries' shares resulting in consolidation scope change	511	-
Other, net	558	41
Net cash provided by (used in) investing activities	(37,736)	(24,878)
Cash flows from financing activities:		
Increase (decrease) in short-term debt, net	(412)	204
Repayments of long-term debt	(698)	(15)
Cash dividends paid	(7,856)	(7,856)
Other, net	(36)	(117)
Net cash provided by (used in) financing activities	(9,002)	(7,784)
Effect of exchange rate change on cash and cash equivalents	519	(703)
Net increase (decrease) in cash and cash equivalents	(43,373)	(465)
Cash and cash equivalents at beginning of period	116,903	62,958
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	190	5
Increase in cash and cash equivalents from newly consolidated subsidiary	-	59
Cash and cash equivalents at end of period	73,720	62,557

(4) Note regarding going concern assumption

Not applicable.

(5) Segment Information

Previous fiscal year (April 1, 2009 - September 30, 2009)

1. Segment information by business segment

Since net sales and operating income from the pharmaceuticals segment account for more than 90% of the consolidated total net sales and operating income, the disclosure of segment information by type of business has been omitted.

2. Segment information by geographical area

Since net sales outside Japan of all segments constituted less than 10% of the consolidated totals, the disclosure of geographical segment information has been omitted.

3. Overseas sales

(millions of yen)

Overseas sales	Consolidated net sales	Rate of overseas sales to consolidated net sales
13,495	198,239	6.8%

(Notes)

1. Overseas sales include export sales of the Company and its domestic subsidiaries and sales of its foreign consolidated subsidiaries other than exports to Japan.
2. Since overseas sales of each segment constituted less than 10% of the consolidated totals for the period, the disclosure of overseas sales by region has been omitted.

Current fiscal year (April 1, 2010 - September 30, 2010)

1. Overview of reportable segments

The Company mainly conducts R&D, manufacturing, purchasing, and sales of pharmaceuticals. And the "pharmaceuticals" segment is the Company's reportable segment.

In the pharmaceuticals segment, the Company conducts business activities of ethical drugs and OTC products in Japan and overseas.

2. Information regarding sales and profit/loss for each reportable segment

The Company's reportable segments consist of only "pharmaceuticals" segment, and as a result the disclosure has been omitted.

3. Information regarding impairment loss and goodwill for each reportable segment

Not applicable.

(Additional information)

From the first quarter, the Company applies "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Statement No. 17, March 27, 2009) and "Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Guidance No.20, March 21, 2008).

(6) Note regarding substantial change in shareholders' equity

Not applicable.